NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018

Haddad, Robert I.; Nasr, Christian; Bischoff, Lindsay A.; Busaidy, Naifa L.; Byrd, David R.; Callender, Glenda G.; Dickson, Paxton V.; Duh, Quan Yang; Ehya, Hormoz; Goldner, Whitney; Haymart, Megan R.; Hoh, Carl K.; Hunt, Jason P.; Iagaru, Andrei; Kandeel, Fouad; Kopp, Peter; Lamonica, Dominick; McIver, Bryan; Raeburn, Christopher D.; Ridge, John A.; Ringel, Matthew D.; Scheri, Randall P.; Shah, Jatin P.; Sippel, Rebecca S.; Smallridge, Robert C.; Sturgeon, Cord; Wang, Thomas J.; Wirth, Lori J.; Wong, Richard J.; Johnson-Chilla, Alyse; Hoffmann, K; Gurski, Lisa A.

doi:10.6004/jnccn.2018.0089

Cited by 301 publications

(289 citation statements)

References 53 publications

(67 reference statements)

Supporting

Mentioning

276

Contrasting

Unclassified

Order By: Relevance

“…We extracted information about targeted therapeutics used in clinical practice for treatment of the cancer types under investigation from the US Food and Drug Administration (FDA) portal [25] and from the National Comprehensive Cancer Network (NCCN) guidelines [32][33][34][35][36][37][38][39][40][41][42][43][44]. The inclusion criterion for a therapeutic was its FDA approval and/or recommendation by the NCCN, category higher than 2B.…”

Section: Clinical Utility Of Drugs and Molecular Targetsmentioning

confidence: 99%

See 1 more Smart Citation

Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology

Zolotovskaia

Sorokin

Petrov³

et al. 2020

IJMS

View full text Add to dashboard Cite

Inter-patient molecular heterogeneity is the major declared driver of an expanding variety of anticancer drugs and personalizing their prescriptions. Here, we compared interpatient molecular heterogeneities of tumors and repertoires of drugs or their molecular targets currently in use in clinical oncology. We estimated molecular heterogeneity using genomic (whole exome sequencing) and transcriptomic (RNA sequencing) data for 4890 tumors taken from The Cancer Genome Atlas database. For thirteen major cancer types, we compared heterogeneities at the levels of mutations and gene expression with the repertoires of targeted therapeutics and their molecular targets accepted by the current guidelines in oncology. Totally, 85 drugs were investigated, collectively covering 82 individual molecular targets. For the first time, we showed that the repertoires of molecular targets of accepted drugs did not correlate with molecular heterogeneities of different cancer types. On the other hand, we found that the clinical recommendations for the available cancer drugs were strongly congruent with the gene expression but not gene mutation patterns. We detected the best match among the drugs usage recommendations and molecular patterns for the kidney, stomach, bladder, ovarian and endometrial cancers. In contrast, brain tumors, prostate and colorectal cancers showed the lowest match. These findings provide a theoretical basis for reconsidering usage of targeted therapeutics and intensifying drug repurposing efforts.

show abstract

Section: Clinical Utility Of Drugs and Molecular Targetsmentioning

confidence: 99%

“…Historically, the treatment standards have been formulated for most types of cancer [32][33][34][35][36][37][38][39][40][41][42][43][44]. However, the underlying treatment schemes are focused primarily on localization or histological characteristics of a tumor but do not consider most projections of its molecular phenotype.…”

Section: Introductionmentioning

confidence: 99%

Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology

Zolotovskaia

Sorokin

Petrov³

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Once MTC has metastasized, there is low likelihood of achieving surgical cure. Thus, prophylactic thyroidectomy is standard-of-care whenever achievable (69). Preoperative staging with ultrasound or cross-sectional imaging (e.g., contrast-enhanced neck CT or MRI) is essential to identify regional lymphadenopathy and to facilitate adequate surgical planning.…”

Section: Pre-symptomatic Surveillance For Men2a and Men2b And Treatmementioning

confidence: 99%

“…These children should undergo annual ultrasound and screening for increased calcitonin levels starting at 3 years of age and proceed to thyroidectomy when elevated levels are detected or at 5 years of age. Metastatic disease is rare if serum calcitonin levels are <40 pg/ml, and neck dissection can often be avoided if cervical adenopathy is not detected by imaging or clinical examination (42,69). …”

Section: Pre-symptomatic Surveillance For Men2a and Men2b And Treatmementioning

confidence: 99%

“…Plasma free metanephrines and normetanephrines, or 24-hour urinary fractionated metanephrines, are the currently recommended screening tests (42). Additionally, biochemical screening for PHEO should be performed prior to any planned surgery and pregnancy, regardless of age (42,69). Pre-operative alpha-adrenergic blockade is essential for patients with catecholamine-secreting PHEOs to mitigate risk of intra-operative hypertensive crisis.…”

Section: Pre-symptomatic Surveillance For Men2a and Men2b And Treatmementioning

confidence: 99%

See 1 more Smart Citation

Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood

Wasserman

Tomlinson

Druker

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

Children and adolescents who present with neuroendocrine tumors are at extremely high likelihood of having an underlying germline predisposition for the Multiple Endocrine Neoplasia (MEN) syndromes, including MEN1, MEN2A and B, MEN4, and Hyperparathyroid-Jaw Tumor (HPT-JT) Syndromes. Each of these autosomal dominant syndromes results from a specific germline mutation in unique genes: MEN1 is due to pathogenic MEN1 variants (11q13), MEN2A and B are due to pathogenic RET variants (10q11.21), MEN4 is due to pathogenic CDKN1B variants (12p13.1), and the HPT-JT Syndrome is due to pathogenic CDC73 variants (1q25). Although each of these genetic syndromes share the presence of neuroendocrine tumors, each syndrome has a slightly different tumor spectrum with specific surveillance recommendations based upon tumor penetrance, including the age and location for which specific tumor types most commonly present. Although the recommended surveillance strategies for each syndrome contain similar approaches, important differences do exist among them. Therefore, it is important for caregivers of children and adolescents with these syndromes to become familiar with the unique diagnostic criteria for each syndrome, and also to be aware of the specific tumor screening and prophylactic surgery recommendations for each syndrome.

show abstract

Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes

Huang

Qian

et al. 2021

JAMA Netw Open

View full text Add to dashboard Cite

IMPORTANCE Hashimoto thyroiditis (HT) has been suggested to be associated with papillary thyroid cancer (PTC) development. However, its association with PTC progression remains unclear.OBJECTIVE To examine the association between HT and PTC presentation and outcomes. DESIGN, SETTING, AND PARTICIPANTSThis retrospective cohort study included a review of patients aged 18 to 75 years who had pathologically confirmed PTC treated at a single center in China

show abstract

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018

Cited by 301 publications

References 53 publications

Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology

Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology

Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood

Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes

Contact Info

Product

Resources

About